Home › Merck to Acquire Afferent Pharmaceuticals
 

Keywords :   


Merck to Acquire Afferent Pharmaceuticals

2016-06-09 23:07:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. & SAN MATEO, Calif. KENILWORTH, N.J. & SAN MATEO, Calif.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Afferent Pharmaceuticals announced today that the two companies have signed a definitive agreement under which Merck will acquire this privately held pharmaceutical company. Afferent Pharmaceuticals is a leader in the development of therapeutic candidates targeting the P2X3 receptor for the treatment of common, poorly-managed, neurogenic conditions. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Michael Close, 267-305-1211orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879orAfferentMedia:Susan Kinkead, 415-509-3610orInvestors:Dulce Dizon, 650-286-1276 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: acquire pharmaceuticals merck

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
15.05Dine and dash couple hit my pizzeria, says owner
15.05Boeing may face criminal prosecution, US says
15.05Indian spices face heat over global safety concerns
15.05'Corrupt ship inspectors demand our food and cargo'
15.05Taylor Swift Eras Tour to boost UK spending by 1bn, says report
15.05Three ways to win the rental property race
15.05Renters in scrum for homes as listing time slashed
14.05Nu Skin Releases 2023 Social Impact and Sustainability Report
More »